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  EVIDENCE-BASED ANSWER 
No evidence exists that treating isolated high triglyceride levels in the absence of other risk factors prevents 
coronary events. Although elevated triglycerides in some studies correlates with coronary events, the 
association weakens when controlled for factors such as diabetes, high-density lipoprotein (HDL) and low-
density lipoprotein (LDL) cholesterol, body mass index, and other cardiac risk factors. 
Coincident lowering of triglycerides, while treating other dyslipidemias (such as high LDL and low HDL), can 
contribute to decreasing coronary events (strength of recommendation [SOR]: A, based randomized controlled 
trials). Treating triglyceride levels over 500 to 1000 mg/dL may reduce the risk of pancreatitis (SOR: C, expert 
opinion). 
  EVIDENCE SUMMARY 
Truly isolated hypertriglyceridemia is rare. To date, no good trials directly address the effect of reducing truly 
isolated hypertriglyceridemia on cardiovascular morbidity or mortality. High triglycerides are usually 
accompanied by other features of the “metabolic syndrome” (low HDL, high LDL, insulin resistance, diabetes, 
hypertension, and obesity), making it almost impossible to look at these in isolation or attribute risk to a specific 
component.1 
Whether high triglyceride levels pose risk in the true absence of these other metabolic factors is controversial. 
One meta-analysis of 17 population-based prospective studies of triglycerides and cardiovascular disease 
(including 57,000 patients) showed high triglyceride levels to be predictive of cardiac events, even when 
adjusted for HDL and other risk factors (age, total and LDL cholesterol, smoking, body mass index, and blood 
pressure).2 After adjusting for these other risk factors, the authors found an increased risk for all cardiac 
endpoints (myocardial infarction, death, etc) of 14% for men and 32% for women (Men: relative risk [RR]=1.14; 
95% confidence interval [CI], 1.05–1.28; Women: RR=1.37; 95% CI, 1.13–1.66). 
Another meta-analysis of 3 prospective intervention trials with 15,880 enrolled subjects found that triglyceride 
levels did not provide any clinically meaningful information about risk beyond that provided by other cholesterol 
subfractions.3 
In treatment trials, the most impressive risk reductions come from the groups who fit the lipid triad of low HDL, 
high LDL, and high triglycerides. Low levels of HDL appear to interact with hypertriglyceridemia to increase 
coronary risk, and all studies showing improved outcomes have simultaneously increased HDL while lowering 
triglycerides.4-6 In 3 large-scale prospective, placebo-controlled trials (the Helsinki Heart Study, a primary 
prevention study, and the VA-HIT and Bezafibrate Infarction Prevention trials, both secondary prevention 
studies), lowering triglycerides and raising HDL concurrently improved outcomes.5 Successful dietary and 
medical interventions, especially with statins and fibrates, improved overall lipid profiles—not just triglyceride 
levels. 
Accordingly, elevated triglycerides should prompt providers to rigorously identify these other risk factors for 
cardiovascular morbidity and mortality, which may not be immediately obvious. In the absence of such other 
factors, no evidence exists to guide therapy. Expert opinion7,8 supported by epidemiologic evidence9 suggests 
that patients with triglyceride levels of 500 to 1000 mg/dL may have an increased risk of pancreatitis. 
Accordingly, providers should consider therapy to lower triglycerides to less than 500 in these patients, 
regardless of accompanying risk factors. 
  RECOMMENDATIONS FROM OTHERS 
The American College of Physicians, the European Society of Cardiology, and the US Preventive Services 
Task Force do not recommend screening for hypertriglyceridemia. Clinical guidelines of the National 
Cholesterol Education Program/Adult Treatment Panel III (NCEP/ATP III), American Heart 
Association/American College of Cardiology, and the American Diabetes Association all support LDL lowering 
as the primary target of therapy based on the patients risk profile.10 NCEP/ATP III has identified triglyceride 
levels of <150 as normal, 150–199 as borderline high, 200–499 as high, and 500 as very high.7 
A patient with high triglycerides should prompt a search for components of the “meta-bolic syndrome” and 
secondary causes, including high dietary fat, high alcohol intake, drugs (steroids, beta-blockers, high-estrogen 
oral contraceptives), medical conditions (hypothyroidism, nephrosis, renal failure, liver disease, Cushing 
disease, and lupus), and rare familial dyslipidemias.7,10,11 
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Elevated triglyceride level? First look at the big 
picture 
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Observing the pendulum swings of medical knowledge over time is one of the hallmarks of 
the experienced family physician. As a student, I was warned of the evils of high 
triglycerides, only to enter a period in the 1970s and 1980s of therapeutic nihilism when 
triglycerides were not thought to be an independent coronary risk factor. 
As outlined here, the pendulum is moving toward a more complex consideration of the 
effect of triglycerides on heart disease—and what we should do about it. Our patients are 
better served when we focus on total coronary risk rather than a specific level of 
triglycerides. An elevated triglyceride level leads me first to look at the glucose. I have 
found several poorly controlled or even new diabetic patients this way. By then following 
the adage to “major on the majors and minor on the minors,” I have focused on glucose 
and LDL control to the benefit of my patients. 
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